用于药物“可开发性”评估的药物吸收体外测试:构建体外临床前数据与临床结果之间的桥梁

In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.

作者信息

Sun Duxin, Yu Lawrence X, Hussain Munir A, Wall Doris A, Smith Ronald L, Amidon Gordon L

机构信息

Ohio State University, College of Pharmacy, Division of Pharmaceutics, Columbus, OH 43210, USA.

出版信息

Curr Opin Drug Discov Devel. 2004 Jan;7(1):75-85.

DOI:
Abstract

Drug 'developability' assessment has become an increasingly important addition to traditional drug efficacy and toxicity evaluations, as pharmaceutical scientists strive to accelerate drug discovery and development processes in a time- and cost-effective manner. The fraction of drug absorbed and the maximum absorbable dose (MAD) can be estimated from in vivo clinical pharmacokinetics, mass balance studies or in vivo drug permeability in humans by different calculation methods. Unfortunately, in vivo data are usually unavailable at the early stages of drug discovery and development, and in vitro screening for the permeability, solubility, activity and toxicity of a drug has become a routine measurement in drug discovery and development. These in vitro data could be used to predict drug 'developability' with different calculation methods before selecting candidates for clinical evaluation. The fraction of drug absorbed in human could be predicted by in vivo human permeability or in vitro Caco2 permeability. For example, if drug permeability in Caco2 cells reaches 13.3 to 18.1 x 10(-6) cm/s, its predicted in vivo permeability in humans would reach 2 x 10(-4) cm/s, and its predicted fraction of drug absorbed would be > 90%, which is defined as highly permeable. The MAD could also be predicted with in vitro permeability, or calculated absorption rate constant. In addition, in vitro solubility and permeability data can also be used for the biopharmaceutics classification system (BCS) and, subsequently, to direct formulation optimization strategies. If drug 'developability' becomes an obstacle for drug delivery based on these in vitro data and predictions at the early stages of drug discovery and development, options such as prodrug approaches could be explored to enhance drug 'developability', in addition to different formulation methods. Therefore, in vitro absorption testing is a highly valuable tool in the decision-making process to select candidates for in vivo clinical studies at early-stage drug discovery and development.

摘要

随着药物科学家努力以节省时间和成本的方式加速药物发现和开发进程,药物“可开发性”评估已成为传统药物疗效和毒性评估中日益重要的补充内容。药物吸收分数和最大可吸收剂量(MAD)可通过体内临床药代动力学、质量平衡研究或采用不同计算方法的人体体内药物渗透性来估算。不幸的是,在药物发现和开发的早期阶段通常无法获得体内数据,因此针对药物的渗透性、溶解性、活性和毒性进行体外筛选已成为药物发现和开发中的常规检测项目。这些体外数据可在选择临床评估候选药物之前,通过不同的计算方法用于预测药物的“可开发性”。人体药物吸收分数可通过人体体内渗透性或体外Caco2渗透性来预测。例如,如果药物在Caco2细胞中的渗透性达到13.3至18.1×10⁻⁶ cm/s,其预测的人体体内渗透性将达到2×10⁻⁴ cm/s,其预测的药物吸收分数将>90%,这被定义为高渗透性。MAD也可通过体外渗透性或计算吸收速率常数来预测。此外,体外溶解性和渗透性数据还可用于生物药剂学分类系统(BCS),进而指导制剂优化策略。如果在药物发现和开发的早期阶段,基于这些体外数据和预测,药物“可开发性”成为药物递送的障碍,除了不同的制剂方法外,还可探索诸如前药方法等选项来提高药物“可开发性”。因此,体外吸收测试是在药物发现和开发早期阶段选择体内临床研究候选药物的决策过程中非常有价值的工具。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索